We have here a rare kind of setup where you are not betting on a business at all; you are betting on a timeline and a set of conditions being met.

One of those just landed, and the spread has not fully disappeared. Stay with this, and you will know exactly what to confirm before committing anything.

Consumer

Restaurant Brands International Inc. (NYSE: QSR) has a fresh catalyst as its renewed share-repurchase program becomes effective today, allowing purchases under a broader $1 billion authorization. Seaport Global also initiated coverage with a Buy rating and an $88 target, calling the company an underappreciated global growth story.

The valuation remains restrained compared with restaurant peers. Seaport estimates a 5.7% forward free-cash-flow yield, versus mid-to-high 4% yields for peers, while QSR trades at roughly 19 times earnings and continues returning capital through dividends and buybacks.

Operating momentum is improving where it matters most. Burger King U.S. comparable sales rose 8.5% in Q2, overall comparable sales increased 3.8%, and adjusted EPS climbed to $1.07, giving you evidence that the valuation gap sits alongside improving fundamentals rather than simple stagnation.

Burger King Is Carrying More Weight

Burger King’s U.S. turnaround is becoming a larger contributor while management continues expanding the global restaurant base. If unit growth returns to 5% and systemwide sales keep improving, higher operating income can combine with repurchases to lift per-share earnings without requiring a premium valuation.

Tim Hortons Still Needs Work

Tim Hortons has slowed, restaurant traffic remains sensitive to consumer spending, and the company still carries meaningful debt, so the discount is well-earned.

Still, your valuation case starts with improving Burger King sales, a peer-leading cash-flow yield, and a sizable repurchase authorization that can directly reduce the share count at the current price.

Housing

D.R. Horton Inc. (NYSE: DHI) authorized an additional $5 billion share-repurchase program, giving the homebuilder fresh room to reduce its equity base. Management expects at least $3.25 billion of fiscal 2026 repurchases, while the new authorization equals nearly 13% of its roughly $39 billion market value.

At approximately $140, DHI trades near 12.6 times forward earnings and 12.3 times trailing free cash flow. Its roughly $3.2 billion in trailing free cash flow produces an 8.2% cash-flow yield, a restrained valuation even during a difficult housing cycle.

Shares outstanding have already fallen more than 8% year over year, while book value per share increased 5% to $84.85. With $6.1 billion in liquidity and a 23% debt-to-capital ratio, you have a balance sheet capable of funding repurchases while competitors remain cautious.

Lower Multiples Make Every Repurchase Work Harder

D.R. Horton spent $2.2 billion buying 14.6 million shares during the first nine months of fiscal 2026. Retiring shares near 12 times earnings can lift per-share results without requiring rapid revenue growth, allowing the company to use a weak housing cycle to build value for remaining shareholders.

Affordability Still Controls the Risk

Nine-month earnings declined 20%, incentives remain elevated, and high mortgage rates continue pressuring demand and margins. A prolonged slowdown could reduce cash generation and slow repurchases, making execution under the $5 billion authorization an important part of your assessment alongside the timing of a housing recovery.

Fintech

Grab Holdings Limited (NASDAQ: GRAB) agreed to buy a 60% controlling stake in Atome Financial for $1.49 billion in cash, adding an established consumer-lending platform with 25 million users and a $1 billion loan portfolio. The deal also raises Grab’s 2028 adjusted EBITDA target to $1.7 billion.

At approximately $3, Grab carries an $11.8 billion market value and ended Q2 with $5.4 billion in net cash. Its resulting enterprise value sits near $6.4 billion, roughly 9 times 2026 adjusted EBITDA guidance of $720 million to $740 million.

Q2 revenue increased 22% to $997 million, while adjusted EBITDA climbed 54% to $168 million. With the shares near $3, you can pair that operating improvement with $450 million in trailing adjusted free cash flow rather than relying entirely on distant lending targets.

Financial Services Changes What Grab Can Earn

Grab expects financial services to generate $500 million in adjusted EBITDA and hold more than $6 billion in loans by 2028. Atome supplies established credit models and lending products, while Grab brings 54 million monthly users.

The remaining 40% will be priced against Atome’s actual performance, limiting the chance of paying the maximum valuation without matching growth.

Credit Growth Can Cut Both Ways

The transaction will not close until 2027, and rising credit losses or weaker cash flow could make the expansion expensive.

Grab’s $5.4 billion net cash position provides room, but repeated acquisitions could steadily reduce that protection. Management must prove that Atome’s loan portfolio deserves your confidence before the $1.7 billion EBITDA target earns a higher multiple.

The Baldwin Group (NASDAQ: BWIN)

This is arithmetic rather than a thesis. A definitive agreement was announced to take the company private in an all-cash transaction, with shareholders receiving $32.50 a share, a premium of roughly 88% to where the stock sat before the deal leaked into the price.

The board approved it unanimously, and an independent special committee signed off separately, which is about as clean a governance picture as these situations offer.

Closing is targeted for early 2027 under customary conditions, so what you are buying is the remaining spread between today’s quote and that number, divided by the months of waiting. Confirm the terms yourself before acting, keep the position small, and take the spread rather than dreaming about it.

ACADIA Pharmaceuticals (NASDAQ: ACAD)

The most followed fair value work on this sits meaningfully above where the shares trade, which is roughly 24% of upside just to reach what a reasonable buyer would call fair rather than generous.

What separates this from the usual mid-cap biotech gamble is that two commercial central nervous system and rare disease drugs are already producing real revenue, so you are not underwriting a binary approval.

The market is pricing it like slow growth pharma while the pipeline and the margin trajectory both say otherwise. Shares sit less than 15% above their 52 week low, which means the base case here is simply the market catching up to what is already visible. Accumulate under $28.

Halozyme Therapeutics (NASDAQ: HALO)

Record second-quarter results put total revenue up 48% year over year with royalty revenue up 50%, and the royalty base is the part worth understanding. Halozyme licenses technology that converts intravenous drugs into subcutaneous injections, so it earns a cut every time a partner successfully makes that switch.

Five new collaboration agreements were signed in the first seven months of the year against an annual goal of three, which tells you demand for that conversion is accelerating rather than maturing.

You get an expanding royalty stream, a disciplined cost line, and a free option on every future conversion. Start a position in the fall conference circuit and add on weakness that holds the post-earnings trend.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge